Liminal Biosciences is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis. The company is advancing promising research in small molecules for a range of diseases related to fibrosis including respiratory, liver and renal diseases. Through a separate business unit called Prometic, the company also focuses on the use of bioseparation technologies to isolate and purify biopharmaceuticals derived from human plasma.
See our social media community guidelines at https://liminalbiosciences.com/social-media-community-guidelines/
Location: Canada, Laval
Employees: 201-500
Total raised: $105M
Founded date: 1994
Investors 3
| Date | Name | Website |
| - | Western Te... | westerntec... |
| - | Thomvest V... | thomvest.c... |
| 23.07.2021 | BDC | bdc.ca/ |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 09.08.2021 | - | $105M | - | - |
Mentions in press and media 2
| Date | Title | Description | Source |
| 09.08.2021 | Liminal BioSciences : Announces Sale of Priority Review Vouc... | LAVAL, QC and CAMBRIDGE, England , Aug. 9, 2021 /PRNewswire/ - Liminal BioSciences Inc. (Nasdaq: LMN... | marketscre... |
| 05.05.2021 | LIMINAL BIOSCIENCES INC. Liminal BioSciences : Notice of An... | Notice of Annual and Special Meeting of Shareholders and Management Information Circular April 19,... | marketscre... |